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Abstract  
Objectives: To investigate clinical correlates of memory complaints (MC) during antiepileptic drug 
(AEDs) treatment in adults with epilepsy with special attention to the role of depression, using user-
friendly standardised clinical instruments which can be adopted in any outpatient setting. 
Materials & methods: Data from a consecutive sample of adult outpatients with epilepsy assessed 
with the Neurological Disorder Depression Inventory for Epilepsy (NDDIE), the Adverse Event 
Profile (AEP) and the Emotional Thermometer (ET) were analysed.  
Results: From a total sample of 443 patients, 28.4% reported MC as “always” a problem. These 
patients were less likely to be seizure free (18.3% vs. 34.3%; p<0.001), had a high number of previous 
AED trials (4 vs. 3; p<0.001) and high AEP total scores (49 vs. 34.2; p<0.001). There was no 
correlation with specific AED type or combination. Depression was the major determinant with a 2-
fold increased risk (95%CI 1.15-3.86; p=0.016). When depression was already known and under 
treatment, patients with MC were less likely to be in remission from depression despite antidepressant 
treatment (11.9% vs. 1.6% p<0.001). Among patients without depression, those reporting MC 
presented with significantly high scores for depression (3.3 vs. 2; t=3.07; p=0.003), anxiety (4.5 vs. 
2.7; t=4.43; p<0.001), anger (3 vs. 2; t=2.623; p=0.009) and distress (3.8 vs. 2.2; t=4.027; p<0.001) 
than those without MC.  
Conclusions: Depression has to be appropriately treated and full remission from depression 
should represent the ultimate goal as sub-threshold or residual mood and anxiety symptoms can 
contribute to MC.  
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Introduction 
The issue of cognitive complaints in epilepsy is still challenging for clinicians especially 
when in the context of treatment emergent adverse events of antiepileptic drugs (AEDs). Patients with 
epilepsy report a degree of subjective impairment in cognitive functioning ranging between 44% for 
difficulties in learning and psychomotor retardation, to 59% for sleepiness or tiredness (1, 2). Most 
importantly, 63% of patients perceive that AEDs prevent them from achieving activities or goals (1). 
It can be challenging for clinicians to understand whether cognitive complaints represent an 
underlying cognitive problem especially when reported in the context of side effects of medications.  
The presence of memory deficits in people with epilepsy is well recognized.  In fact, people with 
epilepsy seek help for memory problems more often than for any other problem (3) and according to 
the NICE Guidelines, memory complaints (MC) represent one of the indications for a 
neuropsychological assessment (4). Several studies have revealed discrepancies between subjective 
MC and the objective results of neuropsychological tests showing that patients who have MC often 
perform within normal limits on standardized memory tests and emotional factors, such as depression 
and anxiety, have to be considered (5-16). It seems evident that spontaneous complaints of memory 
difficulties may overestimate the incidence of the actual impairment (17, 18).  
Mood and anxiety disorders represent the most frequent psychiatric comorbidities in patients with 
epilepsy and reasons for such a close link are both biological and psychosocial (19). In addition, 
difficulties in concentrating and remembering represent specific symptoms of depression, reflecting a 
specific dysfunction in frontal lobe activity (20, 21). It is, therefore, important to investigate the role 
of such comorbidities in patients with MC during AED treatment. The aim of the present study was 
to investigate clinical correlates of MC during AED treatment in adult patients with epilepsy 
with special attention to the role of depression, using user-friendly standardised clinical 
instruments which can be adopted in any outpatient setting. 
  
Material & methods 
Data from a consecutive sample of patients with an established diagnosis of epilepsy 
attending the epilepsy outpatient clinics of the Atkinson Morley Regional Neurosciences Centre, St 
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George’s University Hospitals NHS Foundation Trust in London, were analysed. As part of our 
routine clinical activity, all patients complete the Neurological Disorder Depression Inventory for 
Epilepsy (NDDIE) (22), the Adverse Event Profile (AEP) (23) and the Emotional Thermometer (ET) 
(24).  As per Research Ethic Committee (REC) advice, research limited to secondary use of 
anonymized information previously collected in the course of normal care is excluded from formal 
REC review. Data storage and management was compliant with the Good Clinical Practice statement 
in accordance to the Declaration of Helsinki. 
The NDDI-E is a well-known clinical instrument, developed for the rapid and objective detection of a 
major depressive episode in patients with epilepsy using a cut off score >=15. It has been found to be 
a very practical and user-friendly screening instrument in an outpatient setting. 
The AEP is a 19-item, self-report instrument specifically developed to investigate side effects of 
AEDs. It is possible to analyse the scores of individual symptoms as well as calculate overall 
symptom score. Each symptom is quantified on a four-point likert scale, with 1 indicating that there 
was “never” a problem; 2 “rarely” a problem; 3 “sometimes” a problem; 4 “always” problem.  
The ET is a new screening instrument made up of seven visual analogue scales validated in patients 
with epilepsy. For the screening of depression in epilepsy, the ET showed a sensitivity of 85.1%, a 
specificity of 78.8%, a PPV of 0.463 and a NPV of 0.961. 
 
MC have been identified using the specific subscale of the AEP. Groups were compared for age, 
gender, age of onset and duration of the disease, epilepsy diagnoses, AEDs treatment and 
combinations, seizure frequency, current depression (defined by a positive NDDIE screening), AEP 
and ET scores.  
Frequencies of categorical demographic and clinical variables were analysed using the χ2 analysis or 
Fisher’s exact test. Continuous demographic and clinical variables, AEP and ET scores were 
compared using the Student’s t-test for independent samples.  Correlations were tested using a 
bivariate two-tailed parametric correlation procedure (Pearson’s coefficient). A logistic regression 
model was then constructed with age and gender as potential confounders. The alpha error was set at 
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0.05. All statistical analyses were 2-tailed and conducted using the Statistical Package for Social 
Sciences (Version 15 for Windows, SPSS Inc. Chicago, IL).  
  
Results 
From a total sample of 443 patients, 126 (28.4%) rated “always”, 112 (25.3%) “sometimes”, 
48 (10.8%) “rarely” and 157 (35.4%) “never” for MC. Demographic and clinical variables are shown 
in Table 1. MC subscale correlated with age (r=0.132 p<0.001) but the extent of the correlation was 
quite weak; it did not correlate with age at onset or duration of the epilepsy. Still, MC subscale 
correlated with number of previous AED trials (r= 0.196 p<0.001) but again the extent of the 
correlation was quite weak. Comparing patients who rated “always” vs. the remaining group, patients 
with MC were less likely to be seizure free (18.3% vs. 34.3%; Chi-square = 11.215; df=1; p<0.001), 
had a higher number of previous AED trials (4 vs. 3; t=4.037; p<0.001) and a higher load of adverse 
events in general as demonstrated by the high AEP total score (49 vs. 34.2; t=12.387; p<0.001). There 
was no difference in age, gender, ethnicity, duration and age of onset of the epilepsy, epilepsy 
diagnosis. There was no difference in terms of AEDs regimen (polytherapy vs. duo-therapy vs. 
monotherapy). There was no difference in AED combinations. There was no association with a 
specific AED (i.e. topiramate, levetiracetam, lamotrigine) apart from pregabalin (PGB). In fact, there 
were significantly more patients on PGB among those with MC as compared to those who did not 
(11.1% vs. 0.3%; Chi-Square=32.120; df=1; p<0.001). However, it is important to acknowledge that 
the total number of patients on PGB, in our sample, was very small, namely 15.  
Patients with MC were more likely to be on antidepressant drug treatment (19% vs. 7.3%, Chi-
square=13.220; df=1; p=0.001) and to be currently depressed as defined by the NDDIE (48.4% vs. 
12.3%; Chi-square=67.265; df=1; p<0.001). The association with depression was further supported by 
the correlation between the MC subscale and NDDIE total score (r=0.586; p<0.001). In addition, 
patients with MC presented high scores not only for depression but also for anxiety (6 vs. 2; t=7.419; 
p<0.001), anger (4 vs. 1; t=7,471; p<0.001) and distress (5 vs. 2; t=7.107; p<0.001) as measured with 
the ET. 
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A subsequent regression analysis in the whole sample resulted in a reduced model where only 
depression and total AEP score were significantly associated with MC (Table 2). 
Finally, analysing separately patients with and without current depression (as defined by the NDDIE), 
patients with MC and depression were less likely to be in remission from depression despite the 
antidepressant drug treatment (Not in remission 11.9% vs. In remission 1.6%; Chi-square=22.308; 
df=1; p<0.001) while, in the subgroup of patients without depression, subjects with MC still presented 
significantly elevated scores for depression (3.3 vs. 2; t=3.07;p=0.003), anxiety (4.5 vs. 2.7; t=4.43; 
p<0.001), anger (3 vs. 2; t=2.623; p=0.009) and distress (3.8 vs. 2.2; t=4.027; p<0.001) (Figure 1).  
 
Discussion 
Previous authors have suggested a relationship between MC and emotional distress in patients with 
epilepsy (5-16) and similar results have been found in general medical conditions (25-28). The 
novelty of this study is the delineation of MC in a large sample of patients with epilepsy using 
user-friendly standardised clinical instruments which can be adopted in any outpatient clinic in 
a real life setting. Previous studies in epilepsy were conducted in small groups of patients using 
clinical scales (e.g. Beck Depression Inventory) that can be strongly affected by adverse events of 
AEDs in general and cognitive adverse events in particular (22). On the contrary, the NDDIE has 
been developed in order to minimize the impact of adverse events when screening for depression. In 
fact, in the original NDDIE validation study, AEP scores did not affect the whole model (22). Our 
results clearly suggest that depression has to be actively considered and appropriately treated in 
patients with MC during AED treatment. The prevalence of depression in our sample (22.6%), as 
identified with the NDDIE, is quite in line if not even lower than that reported by the majority of 
studies conducted in tertiary epilepsy centres (22, 29, 30). The link between MC and depression is 
easy to understand. Firstly, mood disorders are associated with neuropsychological deficits per se 
(31). Secondly, patients with depression often believe that their cognitive problems are caused by 
external factors, such as the drug they have to take, instead of by internal factors such as their mood 
state or the epilepsy (2). From our data, it is impossible to understand whether MC represent just 
biological symptoms of depression or patients with depression are more likely to complain of 
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memory problems. Other authors showed that a past history of depression is associated with 
cognitive complaints during treatment with AEDs (32, 33). Further studies using objective 
neuropsychological measures for memory in this group of patients are needed. However, our 
results bring further evidence about the importance of a full remission from depression in patients 
with epilepsy and the role of sub-threshold mood and anxiety symptoms in patients with MC. In our 
sample, 24% of depressed patients in the group of subjects with MC were not in remission from their 
mood disorder despite a first line antidepressant treatment at a correct dosage vs. 12% of depressed 
patients in the comparison group. Obviously, not all these patients could be considered as having a 
drug resistant depression as probably some of them had only recently started on the antidepressant 
treatment.  
Remission and recovery are main goals of the acute treatment of depression and avoiding recurrence 
is the main objective of long-term treatment. Remission applies when all symptoms go away and 
when remission lasts for 6 to 12 months the patient is then considered in a recovery state. In general 
terms, it is estimated that the percentage of response to one treatment or a combination of therapeutic 
interventions is up to 90% of patients with depression and among these subjects about 50% may 
recover within 6 months and up to 75% in 2 years (34). To date, there are no data on remission and 
recovery rates in patients with epilepsy and depression. Our data bring further evidence on the urgent 
need of prospective studies addressing this specific issue. 
 
The role of sub-threshold mood and anxiety symptoms is the second important point raised by our 
study. Even in patients that were not depressed according to the NDDIE, those with MC presented 
with higher scores for mood, anxiety, anger and distress (Figure 1). Although these scores per se 
were not in the pathological range, they obviously suggest the sub-threshold or residual mood and 
anxiety symptoms play a role in MC even when a screening for depression is negative. Previous 
authors pointed out to the role of sub-threshold mood and anxiety symptoms in quality of life of 
patients with epilepsy (35). Our data support the view that these symptoms are implicated in MC 
during AED treatment and should get clinical consideration. 
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Other clinical variables identified by our study worth further discussion. The association with 
poor seizure control and the total number of previous AED trial may suggest that patients with more 
severe, drug-refractory syndromes are more likely to complain of memory problems than those who 
are well controlled. This finding would be in keeping with previous studies emphasizing the role of 
the underlying epileptic syndrome for cognitive problems (36). In this regard, it is interesting to note 
that even newly diagnosed untreated patients with epilepsy seem to be cognitively compromised even 
before they start AEDs, independently by the underlying cause, with memory and psychomotor speed 
being the most severely affected domains (37). The lack of an association with the AED regime 
(either monotherapy or polytherapy) is in keeping with a major role played by disease-related 
variables rather than by treatment-related ones, as already suggested by other authors regarding 
treatment emergent adverse effects of AEDs in general (38). The association between MC and 
depression has to be discussed in such a light. Whether patients with epilepsy and depression 
configure a specific endophenotype characterized by poor response to treatment and increased risk of 
treatment emergent adverse events has to be further explored.  
 
Our results should be considered bearing in mind the following limitations. First, the 
retrospective nature of this study. However, the cross-sectional data on which it is based was collected 
prospectively as part of a previous study aimed at identifying relevant variables using user-friendly 
instruments that can be adopted in any outpatient settings. Neuropsychological tests represent the 
gold standard for memory assessment in epilepsy but our data bring further evidence on the 
need for a multidisciplinary approach and a routine screening for depression in patients with 
epilepsy and MC, depicting a pragmatic way for neurologists to approach the problem of MC in 
a busy outpatient setting. Second, our results may not be representative of the general population of 
patients with epilepsy as they come from a tertiary referral centre where more severe and drug-
refractory cases are present. Third, the NDDIE and ET represent well-known screening instruments 
for a depressive episode but they are not diagnostic of a specific categorical diagnosis per se and a 
subsequent formal psychiatric assessment is needed in order to clarify whether the depressive episode 
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is part of a major depressive disorder, a bipolar disorder or a persistent depressive disorder. However, 
an eloquent disquisition about the underlying psychopathological picture was not our aim.  
Further prospective studies in specific subpopulation of patients with epilepsy are urgently needed in 
order to develop tailored treatment approaches and management plans. 
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Table 1. Demographic and clinical variables in patients in the study sample.  
 
 N = 443 (%) 
Gender 
               Males 
               Females 
 
179 (40.4%) 
264 (59.6%) 
Age, years mean +/- SD 43.1 +/- 15.6 
Age at onset, years mean +/- SD 24.6 +/- 17.8 
Diagnosis 
Focal 
Generalised 
Unclassified 
 
285 (64.3%)  
138 (31.1%) 
20 (4.6%) 
Seizure free 132 (29.8%) 
AED therapy 
Monotherapy 
Duotherapy 
Polytherapy 
 
213 (48.1%) 
160 (36.1%) 
70 (15.8%) 
Total n AED trial, mean +/- SD 3.2 +/- 2.3 
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Table 2. Logistic regression model for memory complaints (adjusted OR for age and gender). 
 
Variable Wald OR 95%CI P value 
Number of AED trial 2.086 1.08 0.97-1.20 n.s. 
AEP Total score 39.654 1.08 1.06-1.11 <0.001 
Depression 5.776 2.10 1.15-3.86 0.016 
Seizure freedom 0.732 0.77 0.42-1.40 n.s. 
 
 
 
 
Figure Legend: Figure 1. Emotional Thermometer (ET) scores in patients with memory 
complaints (MC) with and without depression (Black=MC; Light grey=noMC; *t=3,075 p=0.003; 
**t=4,430 p<0.001; 
§
t=2,623 p=0.009; 
§§
t=4,027 p<0.001). 
 
 
 
 
